Overview

CSL Behring Sclero XIII

Status:
Unknown status
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
Many patients with Scleroderma (Systemic sclerosis) experience damage to blood vessels, mainly to the small arteries. A common manifestation of this is Raynaud's phenomenon (fingers or toes turning white then blue in the cold) and digital ulcers (open sores on the fingertips). The purpose of this study is to see how effective the study drug Human Factor XIII Concentrate is in treating patients who have these and other common manifestation of Scleroderma. It will be given in addition to the accepted treatments used for this disease.
Phase:
Phase 2
Details
Lead Sponsor:
University College, London
Collaborator:
CSL Behring
Treatments:
Factor VIII